A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine With or Without Aura - MK-0974 Pivotal Study 1 - worldwide (with active comparator)

Merck Sharp & Dohme (MSD)0 个研究点目标入组 1,800 人开始时间: 2006年11月22日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Patient has at least 1 year history of migraine (with or without aura).
•Females of child bearing potential must use acceptable contraception throughout trial.
•Patient is in general good health based on screening assessment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patient is pregnant/breast-feeding (or is a female expecting to conceive during study period).
•Patient has uncontrolled hypertension (high blood pressure), uncontrolled diabetes, HIV disease, or other significant disease.
•Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine).
•Patient has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption.
•Patient has a history of cancer within the last 5 years.
•Patient has history or presence of a significant cardiovascular disorder (e.g. acute
•coronary syndrome [e.g. MI or unstable angina]; coronary artery intervention [e.g.
•CABG or PTCA]; congestive heart failure or arrhythmia.
•Note: Patients with evidence of an MI on ECG will be excluded.

发起方

Merck Sharp & Dohme (MSD)